{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:41:33Z","timestamp":1773193293305,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR) modified T cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL). With regulatory approval for tisagenlecleucel and many other agents under active investigation, the use of CAR T cells for ALL continues to expand. While some remissions from anti\u2010CD19 CAR T cells are durable without a consolidative allogeneic stem cell transplantation, CD19 positive and negative relapses remain a significant concern fueling investigations into the biology of CAR T cell persistence and the development of CARTs that target more than 1 antigen. The treatment related toxicities of cytokine release syndrome and neurologic events are potentially life threatening but recent advances have improved understanding and management strategies. This review summarizes outcomes for patients with ALL treated with CD19\u2010CAR T cells while exploring the field's challenges and future directions.<\/jats:p>","DOI":"10.1002\/ajh.25442","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T05:31:05Z","timestamp":1550640665000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Chimeric antigen receptor T cells for acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"94","author":[{"given":"Noelle V.","family":"Frey","sequence":"first","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"1","key":"e_1_2_7_2_1","first-page":"567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology\/the education program of the American Society of Hematology American Society of Hematology education","volume":"2016","author":"Frey NV","year":"2016","journal-title":"Dent Prog"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"1","key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","article-title":"Proceedings from the National Cancer Institute's second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation","volume":"20","author":"Lima M","year":"2014","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"issue":"22","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long\u2010term outcomes following CD19 CAR T cell therapy for B\u2010ALL are superior in patients receiving a Fludarabine\/cyclophosphamide preparative regimen and post\u2010CAR Hematopoetic stem cell transplantation","volume":"128","author":"Lee DW","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7002"},{"key":"e_1_2_7_17_1","first-page":"128","article-title":"Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR\u2010T cell toxicity management","author":"Gardner RLK","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0816-793"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0246-1"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:39:39Z","timestamp":1694378379000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":21,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/ajh.25442"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25442","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]},"assertion":[{"value":"2019-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}